{"id":"venglustat-gz402671","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Injection-site reaction"}]},"_chembl":{"chemblId":"CHEMBL4297611","moleculeType":"Small molecule","molecularWeight":"389.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting glucosylceramidase, venglustat reduces the accumulation of glucosylceramide in cells, which is associated with Fabry disease. This mechanism of action is thought to provide therapeutic benefits for patients with Fabry disease.","oneSentence":"Venglustat is a selective and reversible inhibitor of glucosylceramidase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:25.758Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of adult patients with type 1 diabetes mellitus with a history of severe hypoglycemia requiring medical intervention"}]},"trialDetails":[{"nctId":"NCT05280548","phase":"PHASE3","title":"A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-05-03","conditions":"Fabry Disease","enrollment":104},{"nctId":"NCT05206773","phase":"PHASE3","title":"A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-03-11","conditions":"Fabry Disease","enrollment":122},{"nctId":"NCT04221451","phase":"PHASE3","title":"A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2020-06-29","conditions":"Tay-Sachs Disease, Sandhoff Disease","enrollment":75},{"nctId":"NCT04705051","phase":"PHASE3","title":"Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-02-09","conditions":"Congenital Cystic Kidney Disease","enrollment":24},{"nctId":"NCT05718258","phase":"PHASE1","title":"A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-01-18","conditions":"Hepatic Function Abnormal","enrollment":26},{"nctId":"NCT02843035","phase":"PHASE2","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-01-04","conditions":"Gaucher Disease Type 1, Gaucher Disease Type 3","enrollment":12},{"nctId":"NCT03523728","phase":"PHASE2, PHASE3","title":"A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-10-04","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":478},{"nctId":"NCT03687554","phase":"PHASE1","title":"Effect of Venglustat in Patients With Renal Impairment","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-10-05","conditions":"Healthy Volunteers, Polycystic Kidney, Autosomal Dominant","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Venglustat GZ402671","genericName":"Venglustat GZ402671","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venglustat is a selective and reversible inhibitor of glucosylceramidase. Used for Treatment of adult patients with type 1 diabetes mellitus with a history of severe hypoglycemia requiring medical intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}